Lilly's Inluriyo Shows Positive Results in Advanced Breast Cancer Trial

Eli Lilly's Inluriyo (imlunestrant) has shown positive results in a Phase 3 trial for advanced breast cancer. As monotherapy, it reduced the risk of progression or death by 38% and improved median overall survival by 11.4 months in patients with ESR1-mutated disease. The combination of imlunestrant and abemaciclib reduced the risk of progression or death by 41% and showed a favorable overall survival trend. Safety profiles remained consistent with earlier reports.